Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323334 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT02323334 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 94 participants.
The verdict
NCT02323334, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days with the study drug. Part C will last approximately 11-14 weeks. Part D will last approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may only enroll in one part.
Interventions
- DRUG Itraconazole
- DRUG LY3202626
- DRUG Placebo (Part A, B, C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323334
The ClinicalTrials.gov registry entry for NCT02323334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT02323334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02323334 about?
NCT02323334 is a clinical study titled "A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease". This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a soluti...
What is the current status of trial NCT02323334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2014-12. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02323334?
The interventions under investigation include: Itraconazole (DRUG), LY3202626 (DRUG), Placebo (Part A, B, C) (DRUG).
Who is sponsoring clinical trial NCT02323334?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.